The cool reasoning of the Canadian Supreme Court does not acknowledge or reference “external” pressures or the Eli Lilly v. Canada ISDS case. However, courts do not decide cases in a vacuum. This case seems to have been decided in a pressure cooker.
Goal of implementing most of CETA this summer slips farther from reach.
The US Chamber of Commerce, a federation representing more than three million businesses, has called for stronger IP provisions in the renegotiation of the North American Free Trade Agreement.
Canada and Mexico should push very hard to preserve Chapter 19 of the original NAFTA agreement, which created a mechanism to resolve disputes over anti-dumping and countervailing duty measures, a former Mexican official said.
Through this deal, Swiss pharmaceutical corporations are working to erode India’s ability to produce and supply generic medicines for people across the developing world.
The Consumers’ Association of Penang calls on the Malaysian government not to make changes to the law relating to intellectual property rights to comply with the Trans-Pacific Partnership Agreement.
The opening of the US market to Argentine beef exports and its continued openness to biodiesel from this country will be made conditional on a demand that Argentina change its legislation to expedite the approval of patents on seeds waiting in the pipeline.
Trade Justice Pilipinas expresses its opposition to the Regional Comprehensive Economic Partnership agreement or RCEP
Negotiators must protect public health safeguards that enable developing countries like India to keep supplying life-saving affordable medicines for millions of people worldwide.
Although Canada won in a unanimous decision, the ruling does not, however, guarantee domestic discretion going forward, contrary to the suggestion of some.
Granting data exclusivity for clinical trials would undermine access to medicines.
A certificate of supplemental protection provides up to two years of additional protection after expiry of a patent.
Free trade agreements tend to treat intellectual property as an investment made by investor corporations, allowing private investment disputes to be raised against the host country.
Confidential documents obtained by Public Eye show that Novartis has threatened Colombia with international investment arbitration under its BIT with Switzerland to avoid the issuance of a compulsory license
Ukraine has settled a dispute with American pharmaceutical company Gilead Sciences Inc., following the company’s pursuit of legal remedies in both domestic courts and via investment arbitration.
Novartis battle against Colombian Government highlights the threats to public health posed by the outrageous investor-state dispute settlement regime and bad “trade” deals.
A draft of the Regional Comprehensive Economic Partnership agreement reveals three clauses that could potentially hurt production of important generic drugs
The Tribunal found that Eli Lilly had failed to demonstrate that the promise doctrine constitutes a fundamental or dramatic change in the utility requirement under Canadian patent law or that the promise doctrine is arbitrary and/or discriminatory.
Some of the main TRIPS-plus measures historically pushed for by countries such as the United States or the EU are being again proposed at the EU-Mercosur FTA.
Switzerland is pushing for tighter patent protection, data exclusivity and dropping compulsory licencing under a new free trade agreement.